Cheryl Gault

CIK: 0001839046

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)9 (64.3%)

Position reduction

Option Exercises (M)2 (14.3%)

Derivative conversions

Awards (A)3 (21.4%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

RAPP

Rapport Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (14 total)

RAPP
Rapport Therapeutics, Inc.
Sep 30, 2026
Sale(S)
Direct
2.1K shares at avg. $33.76$70K
RAPP
Rapport Therapeutics, Inc.
Sep 30, 2026
Sale(S)
Direct
7.9K shares at avg. $33.04$262K
RAPP
Rapport Therapeutics, Inc.
Jun 30, 2026
Sale(S)
Direct
3.3K shares at avg. $42.17$140K
RAPP
Rapport Therapeutics, Inc.
Jun 30, 2026
Sale(S)
Direct
1K shares at avg. $43.15$43K
RAPP
Rapport Therapeutics, Inc.
Jun 30, 2026
Sale(S)
Direct
3.8K shares at avg. $41.39$157K
RAPP
Rapport Therapeutics, Inc.
Jun 30, 2026
Sale(S)
Direct
1.9K shares at avg. $40.09$76K
RAPP
Rapport Therapeutics, Inc.
Mar 5, 2026
Sale(S)
Direct
2K shares at avg. $28.93$58K
RAPP
Rapport Therapeutics, Inc.
Feb 2, 2026
Award(A)
Stock Option (Right to Buy)
Direct
132K shares-
RAPP
Rapport Therapeutics, Inc.
Nov 26, 2025
Sale(S)
Direct
5K shares at avg. $30.10$150K
RAPP
Rapport Therapeutics, Inc.
Nov 26, 2025
Exercise(M)
Direct
5K shares at avg. $1.80$9K
RAPP
Rapport Therapeutics, Inc.
Sep 8, 2025
Sale(S)
Direct
5K shares at avg. $38.33$192K
RAPP
Rapport Therapeutics, Inc.
Sep 8, 2025
Exercise(M)
Direct
5K shares at avg. $1.80$9K
RAPP
Rapport Therapeutics, Inc.
Mar 3, 2025
Award(A)
Direct
14K shares-
RAPP
Rapport Therapeutics, Inc.
Feb 3, 2025
Award(A)
Stock Option (Right to Buy)
Direct
129K shares-

		Type	Shares	Price		Ownership
Sep 30, 2026	RAPP Rapport Therapeutics, Inc.	Sale(S)	2,075	$33.76	$70,043	Direct
Sep 30, 2026	RAPP Rapport Therapeutics, Inc.	Sale(S)	7,925	$33.04	$261,813	Direct
Jun 30, 2026	RAPP Rapport Therapeutics, Inc.	Sale(S)	3,308	$42.17	$139,506	Direct
Jun 30, 2026	RAPP Rapport Therapeutics, Inc.	Sale(S)	1,000	$43.15	$43,155	Direct
Jun 30, 2026	RAPP Rapport Therapeutics, Inc.	Sale(S)	3,792	$41.39	$156,964	Direct
Jun 30, 2026	RAPP Rapport Therapeutics, Inc.	Sale(S)	1,900	$40.09	$76,174	Direct
Mar 5, 2026	RAPP Rapport Therapeutics, Inc.	Sale(S)	2,014	$28.93	$58,265	Direct
Feb 2, 2026	RAPP Rapport Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	132,000	-	-	Direct
Nov 26, 2025	RAPP Rapport Therapeutics, Inc.	Sale(S)	5,000	$30.10	$150,487	Direct
Nov 26, 2025	RAPP Rapport Therapeutics, Inc.	Exercise(M)	5,000	$1.80	$9,000	Direct
Sep 8, 2025	RAPP Rapport Therapeutics, Inc.	Sale(S)	5,000	$38.33	$191,650	Direct
Sep 8, 2025	RAPP Rapport Therapeutics, Inc.	Exercise(M)	5,000	$1.80	$9,000	Direct
Mar 3, 2025	RAPP Rapport Therapeutics, Inc.	Award(A)	13,987	-	-	Direct
Feb 3, 2025	RAPP Rapport Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	129,000	-	-	Direct

1-14 of 14 transactions

About Gault Cheryl

Gault Cheryl (SEC CIK 0001839046) files insider reports with the SEC as Chief Operating Officer of Rapport Therapeutics, Inc. (RAPP).

Signal8 holds 8 ownership filings by Gault Cheryl, all Form 4s, filed between Feb 4, 2025 and Oct 1, 2026. Those filings report 14 transactions, from Feb 3, 2025 to Sep 30, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Gault Cheryl's filings is in BOSTON, MA.

Recent filings by Gault Cheryl

Sep 30, 2026: Open-market sales of RAPP shares (2 lines, Form 4, code S).
Jun 30, 2026: Open-market sales of RAPP shares (4 lines, Form 4, code S).
Mar 5, 2026: Open-market sale of RAPP shares (Form 4, code S).
Feb 2, 2026: Grant or award of RAPP derivative securities (Form 4, code A).
Nov 26, 2025: Open-market sale of RAPP shares (Form 4, code S).

Other insiders filing for Rapport Therapeutics, Inc. (RAPP)

HEALY JAMES, Director
Ceesay Abraham, Chief Executive Officer
Sanchez Ramiro, Director
Silva Paul M, Director
Young Wendy B., Director
PAUL STEVEN M, Director

How to read Form 4 transaction codes